2024
Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma.
Bitar R, Salem R, Finn R, Greten T, Goldberg S, Chapiro J. Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma. Radiology 2024, 313: e232875. PMID: 39560477, PMCID: PMC11605110, DOI: 10.1148/radiol.232875.Peer-Reviewed Original ResearchConceptsManagement of hepatocellular carcinomaHepatocellular carcinomaLocoregional therapyClinical trialsImage-guided locoregional therapiesEnd pointsStages of hepatocellular carcinomaTumor microenvironment mechanismsCatheter-directed therapyCombination of immunotherapyProspective clinical trialImaging end pointsStandard of careAdjuvant settingNovel immunotherapiesCombination therapyTherapy resistanceInterventional radiologistsImmunotherapyDisease stageTherapyDisease evolutionNovel biomarkersCarcinomaMicroenvironment mechanisms
2021
Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative
Puijk R, Ahmed M, Adam A, Arai Y, Arellano R, de Baère T, Bale R, Bellera C, Binkert C, Brace C, Breen D, Brountzos E, Callstrom M, Carrafiello G, Chapiro J, de Cobelli F, Coupé V, Crocetti L, Denys A, Dupuy D, Erinjeri J, Filippiadis D, Gangi A, Gervais D, Gillams A, Greene T, Guiu B, Helmberger T, Iezzi R, Kang T, Kelekis A, Kim H, Kröncke T, Kwan S, Lee M, Lee F, Lee E, Liang P, Lissenberg-Witte B, Lu D, Madoff D, Mauri G, Meloni M, Morgan R, Nadolski G, Narayanan G, Newton I, Nikolic B, Orsi F, Pereira P, Pua U, Rhim H, Ricke J, Rilling W, Salem R, Scheffer H, Sofocleous C, Solbiati L, Solomon S, Soulen M, Sze D, Uberoi R, Vogl T, Wang D, Wood B, Goldberg S, Meijerink M. Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative. Radiology 2021, 301: 533-540. PMID: 34581627, DOI: 10.1148/radiol.2021203715.Peer-Reviewed Original ResearchConceptsImage-guided tumor ablationTime-to-event end pointsEnd pointsTumor ablationOncologic end pointsOncological outcome measuresOutcome measuresPatient-reported outcome questionnairesClinical outcome measuresInterventional oncologyConsensus guidelinesClinical trialsHealth economic issuesCancer trialsQuality of lifeConsensus documentOutcomes QuestionnaireDATECANAssess outcomesReport outcomesOncology researchInternational panelTrialsAblationOutcomesLipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial
Letzen BS, Malpani R, Miszczuk M, de Ruiter QMB, Petty CW, Rexha I, Nezami N, Laage-Gaupp F, Lin M, Schlachter TR, Chapiro J. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. Clinical Imaging 2021, 78: 194-200. PMID: 34022765, PMCID: PMC8364875, DOI: 10.1016/j.clinimag.2021.05.007.Peer-Reviewed Original ResearchConceptsConventional trans-arterial chemoembolizationMedian overall survivalProspective clinical trialsLipiodol depositionTumor responsePredictive biomarkersClinical trialsModified Response Evaluation CriteriaPost-TACE CTResponse Evaluation CriteriaMetastatic liver cancerKaplan-Meier analysisTrans-arterial chemoembolizationTumor response criteriaLiver tumor responsePrediction of survivalSelective drug targetingArterial embolizationLiver metastasesOverall survivalBland-Altman plotsTransarterial chemoembolizationPortal veinTumor respondersHepatocellular carcinoma
2020
Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies
Savic LJ, Chapiro J, Funai E, Bousabarah K, Schobert IT, Isufi E, Geschwind JH, Stark S, He P, Rudek MA, Perez Lozada JC, Ayyagari R, Pollak J, Schlachter T. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. European Radiology 2020, 31: 3002-3014. PMID: 33063185, DOI: 10.1007/s00330-020-07380-w.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationProspective clinical trialsTumor responseConventional TACEAdverse eventsTransarterial chemoembolizationLiver malignanciesClinical trialsMarker predictiveTumor volumeExact testChild-Pugh B classVolumetric tumor responseChild-Pugh BPeak concentrationNon-compartmental analysisFisher's exact testDose normalizationQuantitative European AssociationStandard non-compartmental analysisTime-concentration curveLiver criteriaLobar distributionDoxorubicin pharmacokineticsNeuroendocrine metastases
2019
Interventional oncology: aiming globally to be the 4 th pillar of cancer care
Madoff DC, Chapiro J, Pua U. Interventional oncology: aiming globally to be the 4 th pillar of cancer care. Chinese Clinical Oncology 2019, 8: 56. PMID: 31968980, DOI: 10.21037/cco.2019.12.12.Peer-Reviewed Original ResearchConceptsIO therapyInterventional oncologyClinical OncologyNational Comprehensive Cancer NetworkComprehensive Cancer NetworkDisease treatment guidelinesOncologic patient managementOncologic communityPalliative settingTreatment guidelinesOncologic careInterventional oncologistsMedical oncologyCancer careClinical trialsTreatment strategiesPatient managementPatient allocationCancer NetworkInterventional radiologyOncologyTherapyEuropean SocietyRadiation oncologyAmerican Society
2016
Interventional Oncology in Hepatocellular Carcinoma
Mu L, Chapiro J, Stringam J, Geschwind JF. Interventional Oncology in Hepatocellular Carcinoma. The Cancer Journal 2016, 22: 365-372. PMID: 27870678, PMCID: PMC5125535, DOI: 10.1097/ppo.0000000000000227.Peer-Reviewed Original ResearchConceptsInterventional oncologyLocoregional therapyHepatocellular carcinomaInterdisciplinary clinical practiceTumor response assessmentOngoing clinical trialsComplex clinical problemImmune response pathwaysTransarterial chemoembolizationCancer careCombination therapyClinical managementClinical trialsRadiofrequency ablationResponse assessmentSystemic effectsClinical problemClinical practiceEmbolic materialTherapyCancer treatmentIntraprocedural imagingOncologyRadiation oncologyCarcinoma
2014
Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
Chapiro J, Sur S, Savic LJ, Ganapathy-Kanniappan S, Reyes J, Duran R, Thiruganasambandam SC, Moats CR, Lin M, Luo W, Tran PT, Herman JM, Semenza GL, Ewald AJ, Vogelstein B, Geschwind JF. Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer. Clinical Cancer Research 2014, 20: 6406-6417. PMID: 25326230, PMCID: PMC4300523, DOI: 10.1158/1078-0432.ccr-14-1271.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaSuit-2 cell lineOrthotopic xenograft mouse modelBioluminescence imagingFavorable toxicity profileSublethal drug concentrationsAnti-invasive effectsXenograft mouse modelPDAC cell linesCell linesXenograft tumor modelHalf maximal inhibitory concentrationStrong anticancer effectsPancreatic cancerClinical trialsDuctal adenocarcinomaMouse modelToxicity profileIC50 profileTherapeutic efficacyMatrigel invasionVivo efficacyBLI signalMatrigel assaysMiaPaCa-2Combination of intra-arterial therapies and sorafenib: Is there a clinical benefit?
Chapiro J, Duran R, Geschwind JF. Combination of intra-arterial therapies and sorafenib: Is there a clinical benefit? La Radiologia Medica 2014, 119: 476-482. PMID: 24894921, DOI: 10.1007/s11547-014-0413-0.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBiomarkers, TumorCarcinoma, HepatocellularChemoembolization, TherapeuticEmbolization, TherapeuticHepatectomyHepatic ArteryHumansInfusions, Intra-ArterialLiver NeoplasmsMicrospheresNeoplasm StagingNiacinamidePhenylurea CompoundsRadiography, InterventionalSorafenibSurvival RateConceptsIntra-arterial therapySurvival benefitIntroduction of sorafenibLoco-regional approachesAdvanced stage diseaseSignificant survival benefitUnresectable hepatocellular carcinomaLocal tumor controlTreatment of patientsSequence of administrationConventional systemic chemotherapyInternational clinical trialsOral monotherapySystemic chemotherapyExciting new optionsClinical outcomesTransarterial chemoembolizationClinical benefitSafety profileTumor controlClinical trialsHepatocellular carcinomaNovel agentsPotential biomarkersSystemic toxicity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply